Terumo Corp. (OTCMKTS:TRUMY – Get Free Report) was the recipient of a significant decline in short interest during the month of May. As of May 15th, there was short interest totaling 14,067 shares, a decline of 54.4% from the April 30th total of 30,823 shares. Based on an average daily volume of 679,301 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.0% of the company’s stock are short sold.
Wall Street Analyst Weigh In
TRUMY has been the subject of several research analyst reports. Nomura upgraded Terumo to a “hold” rating in a report on Tuesday, February 24th. Zacks Research raised shares of Terumo to a “hold” rating in a report on Thursday, April 9th. Two analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold”.
Check Out Our Latest Report on TRUMY
Terumo Stock Performance
Terumo (OTCMKTS:TRUMY – Get Free Report) last announced its earnings results on Friday, May 15th. The company reported $0.11 EPS for the quarter, meeting analysts’ consensus estimates of $0.11. Terumo had a net margin of 12.09% and a return on equity of 9.35%. The business had revenue of $1.90 billion during the quarter, compared to analysts’ expectations of $1.84 billion. Research analysts forecast that Terumo will post 0.63 earnings per share for the current fiscal year.
About Terumo
Terumo Corporation (OTCMKTS: TRUMY) is a Japan-based medical technology company that develops, manufactures and markets a broad range of healthcare products for hospitals, clinics and blood centers. Its businesses encompass cardiovascular systems, general hospital products and blood management and cell technologies, supplying devices used in interventional and surgical procedures as well as everyday clinical care. Terumo sells consumables and capital equipment intended to support patient care across acute and ambulatory settings.
Key product categories include vascular access and interventional devices (such as guidewires, catheters and delivery systems), cardiac and cardiopulmonary surgical equipment, infusion therapy products (including infusion pumps and disposables), syringes and blood bags.
See Also
- Five stocks we like better than Terumo
- These 3 CLO ETFs Target a Niche Corner of the Fixed-Income Market
- 3 Ways to Play the Data Center Land Grab
- The Smarter Way to Invest in AI Without Taking Extreme Risk
- 3 Dividend Kings That Earn Their Crown Every Quarter
Receive News & Ratings for Terumo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Terumo and related companies with MarketBeat.com's FREE daily email newsletter.
